The Three Most Critical Changes for Business Leaders
While the QMSR incorporates hundreds of pages of ISO 13485, three specific changes demand immediate attention from a leadership perspective.
| Critical Change | What It Means for Your Business |
|---|
| 1. New Inspection Program (CP 7382.850) | The old QSIT inspection checklist is gone. FDA inspectors now use a risk-based approach, focusing on six Quality Management System (QMS) Areas. They have more discretion to probe areas they deem high-risk, making inspections less predictable and more focused on total product lifecycle risk management. |
| 2. Management Reviews & Internal Audits are Now Fair Game | Under the old QSR, management review outputs and internal audit reports were explicitly excluded from FDA inspection. This protection is now gone. The QMSR allows inspectors to request and review these sensitive documents, demanding a new level of rigor and inspection-readiness for your internal governance processes. |
| 3. Risk Management is Central | While always important, risk management is now the explicit, central pillar of the entire QMS. The new inspection program is designed to identify failures in risk management throughout the product lifecycle, and such failures can now directly lead to "Official Action Indicated" (OAI) findings, triggering potential regulatory action. |
These changes mean that simply being ISO 13485 certified is not enough. Manufacturers must ensure their implementation is robust, their risk management is comprehensive, and their internal documentation can withstand direct regulatory scrutiny.
The Strategic Role of MDSAP in the QMSR Era
The Medical Device Single Audit Program (MDSAP) allows a single regulatory audit to satisfy the requirements of multiple countries, including the United States, Canada, Australia, Brazil, and Japan. While the FDA has clarified that QMSR inspections will not follow the MDSAP audit plan, for Hong Kong manufacturers, participating in MDSAP is no longer just an efficiency play—it is a powerful strategic response to the challenges of the QMSR.
- Proactive Compliance with a Risk-Based Approach
The MDSAP audit model is inherently risk-based and process-oriented, mirroring the philosophy of the FDA's new inspection program. Companies that have successfully undergone MDSAP audits are already accustomed to demonstrating how risk management is integrated throughout their QMS, giving them a significant advantage in preparing for a QMSR inspection.
An MDSAP audit is a rigorous, multi-day examination of your entire QMS against the requirements of ISO 13485 and the specific regulations of participating countries. It serves as the perfect
"dress rehearsal" for a QMSR inspection, identifying weaknesses in a controlled audit environment before they become findings in a regulatory inspection. This is particularly crucial now that internal audit and management review documents are subject to FDA review.
- Demonstrating a Commitment to Global Best Practices
While not a substitute for an FDA inspection, holding an MDSAP certificate sends a powerful signal to the FDA that your organization is committed to the highest standards of global quality management. It demonstrates a level of maturity and proactive compliance that can build confidence with regulators.
- Unlocking Global Market Access
For any Hong Kong manufacturer looking beyond the U.S., MDSAP is a key that unlocks multiple major markets with a single, predictable audit process. It streamlines global expansion, reduces audit fatigue, and provides a significant competitive advantage over companies navigating each country's regulations separately.
Your Action Plan
For Hong Kong medical device manufacturers exporting to the U.S., the path forward is clear:
- Don't Assume ISO 13485 Certification is Enough: Conduct a detailed gap analysis between your current QMS, the full requirements of ISO 13485:2016, and the specific FDA add-ons retained in the QMSR.
- Treat Internal Audits as if They Are FDA Audits: Elevate the rigor of your internal audit and management review processes. Ensure documentation is clear, concise, and inspection-ready.
- Embrace MDSAP as a Strategic Tool: If you are not already part of the program, now is the time to evaluate MDSAP. It is the single most effective way to ensure your QMS is robust, risk-focused, and ready for the new era of FDA inspections, while simultaneously streamlining your access to other key global markets.
DQS is a globally recognized MDSAP Auditing Organization. Our expert auditors in Hong Kong and across Asia can help you navigate the transition to QMSR, conduct a strategic gap analysis, and leverage the power of MDSAP to ensure compliance and unlock global market access.
Associated Services by DQS HK
